Traders Watch List: Nabors Industries Ltd. (NYSE:NBR), Sanofi SA (ADR) (NYSE:SNY)

On Tuesday, Shares of Nabors Industries Ltd. (NYSE:NBR), added 3.63% and closed at 13.14 in the last trading session. The last trading range of the stock ranges between $12.82 and13.15. Nabors Industries Ltd., together with its auxiliaries, provides drilling and rig services. It offers equipment manufacturing, rig instrumentation, optimization software, and directional drilling services; and patented steering systems and rig instrumentation software systems, counting ROCKIT directional drilling system that provides data collection services to oil and gas exploration and service companies, and RIGWATCH software, which monitors a rig’s real-time performance and daily reporting for drilling operations. The company also manufactures and sells top drives, catwalks, wrenches, draw works, and other drilling related equipment; and offers well-site services, such as engineering, transportation and disposal, construction, maintenance, well logging, directional drilling, data collection, and other support services.

Sanofi SA (ADR)(NYSE:SNY), jumped 1.02% and closed at $37.73 in the last trading session. The last trading range of the stock ranges between 37.72and37.97. The company’s Market capitalization is $95.93 Billion with the total Outstanding Shares of 1.29 Billion. Sanofi researches, develops, manufactures, and markets various therapeutic solutions. The company operates in three segments: Pharmaceuticals, Vaccines, and Animal Health. It offers Lantus, Apidra, and Insuman that are human insulin analogs; Amaryl, an oral sulfonylurea; Lyxumia, a glucagon-like peptide-1 receptor agonist; Toujeo, an insulin glargine; and Afrezza, an inhaled insulin. The company also provides Praluent, a human monoclonal antibody; and Multaq, a multichannel blocker with anti-arrhythmic properties. In addition, it offers Cerezyme, an enzyme replacement therapy to treat gaucher disease; cerdelga, an oral therapy for Gaucher disease Type 1; Myozyme/Lumizyme for the pompe disease treatment; Fabrazyme for fabry disease treatment; and Aldurazyme to treat mucopolysaccharidosis Type 1, in addition to provides Aubagio and Lemtrada for multiple sclerosis. In addition, it provides Jevtana for prostate cancer; Taxotere for breast, prostate, gastric, lungs, and head and neck cancer treatment; Eloxatin for the treatment of stage III colon cancer; Thymoglobulin to treat acute rejection; Mozobil for treating hematologic malignancies; and Zaltrap for oxaliplatin resistant metastatic colorectal cancer. Further, the company offers other prescription drugs, such as Plavix/Iscover for atherothrombosis and acute coronary syndrome; Lovenox/Clexane for the treatment of venous thromboembolism; Aprovel/Avapro/Karvea for hypertension and nephropathy; Renagel/Renvela to treat chronic kidney disease; Allegra/Telfast to treat seasonal allergic rhinitis and uncomplicated hives; Stilnox/Ambien/Myslee for insomnia treatment; and Synvisc/Synvisc-One for the treatment of osteoarthritis pain. In Addition To, it offers consumer health care products and generic medicines; and vaccine and animal health products.

Leave a Reply

Your email address will not be published. Required fields are marked *